Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?

Alnylam’s stock fell more than 40% in after-hours trading following the decision to end development of revusiran based on an imbalance of deaths in the Phase III ENDEAVOR clinical trial, but executives see no read-through to the rest of the company’s RNAi platform.

Alnylam Pharmaceuticals Inc. offered few details on Oct. 5 about why deaths in the revusiran arm of the Phase III ENDEAVOR clinical trial were more frequent than in the placebo arm, and it’s unclear whether the failed drug’s problems were tied to efficacy, safety or both.

Alnylam fell 41.6% in after-hours trading to $41.04 per share after the company said it discontinued development of revusiran –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By 

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.